Tyr-hGH 177-191
Also known as: Tyr-hGH 177-191, Tyrosine HGH Fragment
Tyr-hGH 177-191 is a tyrosine-extended analog of the C-terminal lipolytic fragment of human growth hormone. The added tyrosine residue is used mainly to enable labeling and tracing while the fragment retains the fat-mobilizing activity associated with the 176-191 region.
Last updated
Mechanism of Action
The growth hormone 177-191 sequence corresponds to the C-terminal region of hGH that carries the hormone's lipolytic activity without its growth-promoting or insulin-antagonizing effects. This fragment is thought to act on beta-3 adrenergic-linked pathways in adipose tissue, stimulating hormone-sensitive lipase and promoting triglyceride breakdown and fatty-acid release while sparing IGF-1 induction. The N-terminal tyrosine addition in the Tyr-hGH analog provides a residue for radioiodination or other labeling so the fragment can be tracked in binding and distribution studies, while preserving the core fat-mobilizing behavior.
- Half-life
- Short, on the order of roughly 20-40 minutes consistent with small hGH fragments
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Targets adipose tissue to promote lipolysis
- Lacks the growth-promoting effects of full-length growth hormone
- Does not meaningfully raise IGF-1 in models
- Tyrosine tag enables tracing and binding research
- Investigated for fat-loss research without insulin antagonism
Potential Side Effects
- Injection-site irritation or redness
- Transient flushing or headache
- Sparse human safety data
- Possible mild lethargy reported anecdotally
Common Dosing
No standardized human protocol exists; the analog is primarily a research and labeling tool. Provided for research and educational reference only, not as personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Pregnancy and breastfeeding
- Active malignancy without specialist oversight
- Known hypersensitivity to growth hormone fragments
HGH Fragment 176-191
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone studied primarily for its fat-reducing effects without the broader growth-promoting actions of full-length GH. It is a popular research compound for lipolysis.
MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region that acts as a regulator of metabolism. It is studied for improving insulin sensitivity, metabolic flexibility, and exercise capacity.
AICAR
AICAR (Acadesine) is an AMPK-activating compound studied as an exercise-mimetic for endurance and metabolic effects in animals. Note: AICAR is a small-molecule nucleoside (an AMPK activator), not a peptide, but is commonly sold alongside research peptides.
- View
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
2001
- View
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2000
- View
Detection and in vitro metabolism of AOD9604
2015
- View
Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone
1993